Bone Biologics Corporation
BBLG · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.09 | 0.29 | -14.47 |
| FCF Yield | -48.21% | -133.91% | -49.58% | -1.13% |
| EV / EBITDA | 48.81 | 8.57 | 0.08 | -92.85 |
| Quality | ||||
| ROIC | -121.11% | -324.39% | -61.62% | -16.77% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.00 | 1.07 | 2.40 | 0.76 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 56.83% | -167.90% | -190.33% | -187.77% |
| Safety | ||||
| Net Debt / EBITDA | -31.03 | -6.31 | 1.71 | 6.05 |
| Interest Coverage | 0.00 | 0.00 | -5.01 | -1.37 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |